


Merestininb

03/20

ALTERNATE NAMES: LY2801653; N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide; N-(3-Fluoro-4-[[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy]phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide

CATALOG #: B3007-1 1 mg
B3007-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₃₀H₂₂F₂N₆O₃

MOLECULAR WEIGHT: 552.5

CAS NUMBER: 1206799-15-6

APPEARANCE: White to off-white solid powder

PURITY: >98%

SOLUBILITY: ~30 mg/ml in DMSO

DESCRIPTION: Merestininb is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K_i) of 2 nM. It shows more anti-proliferative activity in cell lines with MET gene amplification (MKN45, Hs746T and H1993) than cell lines without MET gene amplification (U-87MG, KATO-III). It shows anti-tumor growth activity in U-87MG, and H441 xenograft models with a dosing of 4 or 12 mg/kg, once or twice daily. It also shows potent inhibitory activity against several other oncogenic proteins, including MST1R, FLT3, AXL, PDGFRA, ROS1, TEK, DDR1/2 and MKNK-1/2.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Yan, S.B., Peek, V.L., Ajamie, R., et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. *Invest New Drugs* 31(4), 833-844 (2013).

RELATED PRODUCTS:

Avitinib (Cat. No. B2995)
 Zanubrutinib (Cat. No. B2512)
 Capmatinib (Cat. No. B3005)
 Savolitinib (Cat. No. B3006)
 Theliatinib (Cat. No. B3004)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*